This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Oct 2020

MedPharm is people’s choice after inaugural CPHI Innovation in Response to COVID-19 Pitch Session

MedPharm was the people’s choice for the inaugural CPHI Innovation in Response to COVID-19 award after an absorbing Pitch Session, sponsored by Pharmathen, in which invited shortlisted finalists each pitched their entry to the event’s virtual audience.

2020 was an extraordinary year with extraordinary challenges. As champions of innovation in Pharma, CPHI introduced the new category to the 17th edition of the CPHI Pharma Awards.

The category is designed to recognise innovation in technologies, products, processes, and services to combat the impact of COVID-19 on individuals, patients, healthcare professionals and communities. This includes the development and manufacture of potential vaccines, drug products and medical equipment and the introduction of services, solutions and resources to provide support to those effected by the pandemic.

CPHI had an overwhelming response and our jury shortlisted eight finalists in this category: Aptar Pharma (ActivShield™ by Aptar CSP Technologies), Beximco Pharmaceuticals, Catalent, Crystec Pharma, mSAS® Technology, Dr Reddy’s, Farmalabor srl, Ridgeback Biotherapeutics (MK-4482 – in collaboration with Merck) and MedPharm.

Most of these companies delivered their entry pitches to the CPHI virtual audience, who in turn were invited to review and select their favourite entry.

In the winning pitch, MedPharm’s Chief Technology Officer, Dr John Lenn, said the company’ nomination had come as a direct result of its efforts in pioneering and refining new approaches for the development of new cost-effective in vitro models for nasal and lung epithelial tissue.

“Additionally, in response to the pandemic, MedPharm tailored its unique model to allow companies to assess therapeutic effectiveness of candidates against members of the Coronaviridae family,” he said.

Introducing the pitch session, Gareth Williams, Vice President of Business Development at Pharmathen said his company remains committed to its efforts to deal with COVID-19: “As you all know, we may be facing these challenges for some time yet and we firmly believe that the steps we have taken to date will put the company in a stronger position to ensure safeguarding measures that may be required in the future.”

Beximco Pharmaceuticals of Bangladesh was the jury’s choice for the category for its quick launch of several repurposed drugs, and the launch of the world’s first generic version of Remdesivir.

Mentioned Companies
Pharmathen SA
View company profile

Related News